Testosterone for trans men: what TikTok gets right and wrong

What did @alexandereadie actually say?

The creator told followers that one of testosterone's biggest risks is making your blood "too thick," pointing to elevated hematocrit as the main culprit. He connected this directly to strokes, heart attacks, and other cardiovascular events, and tied it to dosing that exceeds what your body can metabolize. He also recommended blood work every six months to a year as the standard monitoring window.

To his credit, he framed this as a learning conversation, not medical advice, and he emphasized that individual tolerance varies. That kind of epistemic humility is rare in the TRT-content corner of TikTok, where guys are usually telling you to pin 500mg and feel invincible.

Does the science back this up?

Yes, mostly. Testosterone-induced erythrocytosis, meaning a rise in red blood cell mass and hematocrit, is one of the most consistently documented adverse effects of testosterone therapy. The mechanism is real and reasonably well understood.

Testosterone stimulates erythropoiesis, primarily by suppressing hepcidin and increasing erythropoietin sensitivity in the kidneys (Bachman et al., 2014, Journal of Clinical Endocrinology and Metabolism). Hematocrit values above 54% are generally flagged as a threshold requiring clinical intervention, per the 2018 Endocrine Society guidelines. Elevated hematocrit increases blood viscosity, which does raise theoretical cardiovascular risk. However, the direct causal chain between testosterone-induced erythrocytosis and stroke or heart attack in otherwise healthy individuals is murkier than the creator implied. Most cardiovascular events in the literature occur in men with pre-existing risk factors, not in isolation from them (Xu et al., 2016, BMC Medicine).

What did they get wrong or right?

The creator got the core biology right but fumbled the terminology in a way that matters. He called it a "high hematics count," which is not a real clinical term. He likely meant hematocrit or possibly hemoglobin. Hematocrit and hemoglobin are related but distinct measurements, and neither is called hematics. For a video specifically meant to educate the trans masculine community about testosterone risks, that imprecision is a problem. Someone hearing "hematics" will not know what to ask their doctor to test.

The cardiovascular framing was also somewhat overbroad. Saying that thick blood "creates" strokes and heart attacks implies a more direct causation than the evidence supports. Elevated hematocrit is a risk factor, not a guarantee. The creator did hedge slightly by saying conditions "may or may not run in the family," which shows he understands individual variability, but the overall framing leaned dramatic.

On monitoring frequency, the six-month to one-year recommendation is reasonable and consistent with clinical guidance, though many practitioners monitor more frequently in the first year of therapy.

What should you actually know?

If you are on testosterone therapy, erythrocytosis is a genuine concern worth tracking, but it is manageable with proper monitoring. A complete blood count is the standard test. Hematocrit above 54% typically prompts a dose reduction, a change in injection frequency, or therapeutic phlebotomy in persistent cases.

The risk is not evenly distributed. People who smoke, have sleep apnea, or have pre-existing cardiovascular conditions face meaningfully higher risk from elevated hematocrit. Hydration also affects viscosity, which is an underappreciated practical point. Injection frequency matters too: weekly or twice-weekly injections tend to produce lower hematocrit peaks than less frequent large injections, because they avoid the sharp hormone spikes that drive erythropoiesis hardest (Grech et al., 2014, Asian Journal of Andrology).

Six-month monitoring is a floor, not a ceiling. If you are new to testosterone therapy, quarterly checks in the first year give you a much clearer picture of how your body is responding before settling into a longer interval.

Bottom line

This video is more accurate than the average TikTok on testosterone risks, which is a low bar, but he clears it. The science supports the general warning. The clinical terminology was loose, the causal language was a bit dramatic, and calling it the "largest" risk is debatable when polycythemia is highly manageable with monitoring. But the core message, which is that blood work matters and thick blood is a real concern on T, is worth hearing.